Description

TOFACITINIB 2%

• A Janus kinase inhibitor, provides a novel safeand effective therapy option for atopic dermatitis
• Inhibits IL-4 cytokines directly thus leads to rapid attenuation of JAK-STAT signaling in keratinocytes
• Shows rapid onset of efficacy with increasing improvement up to week 4
• Reduces the inflammation that fuels diseases like eczema and vitiligo
• Study shows that 2% ointment was an effective option in patient with localized Granuloma annulare

Indicated In

• Mild to Moderate Atopic Dermatitis (AD)
• Vitiligo
• Alopecia Areata
• Plaque Psoriasis